logo
Plus   Neg
Share
Email

Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS - Quick Facts

Amgen (AMGN) said Friday that the Phase 3 CANDOR study evaluating KYPROLIS in combination with dexamethasone and DARZALEX or KdD compared to KYPROLIS and dexamethasone alone met its primary endpoint of progression-free survival.

The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with KdD.

The CANDOR data will be submitted to a future medical meeting and discussed with health authorities in preparation for regulatory submissions, the company said in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT